Barusiban

Barusiban (INN) (code name FE-200440) is a non-peptide drug which is among the most potent and selective oxytocin receptor antagonists known.[1][2] It was trialed by Ferring Pharmaceuticals as a treatment of preterm labor but failed to demonstrate effectiveness and was not pursued any further.[1][3]

Barusiban

Clinical data
ATC code	None
Identifiers
IUPAC name (4S,7S,10S,13S,16R)-N-[(2S)-5-Amino-1-hydroxy-2-pentanyl]-7-(2-amino-2-oxoethyl)-10-[(2R)-2-butanyl]-13-sec-butyl-16-(1H-indol-3-ylmethyl)-N-methyl-6,9,12,15,18-pentaoxo-1-thia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide
CAS Number	285571-64-4
PubChem CID	9832431
ChemSpider	8008159
UNII	UX33I93GLS
CompTox Dashboard (EPA)	DTXSID20182771
Chemical and physical data
Formula	C40H63N9O8S
Molar mass	830.06 g·mol^−1
3D model (JSmol)	Interactive image
SMILES CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCSCCC(=O)N[C@@H](C(=O)N1)CC2=CNC3=CC=CC=C32)C(=O)N(C)[C@@H](CCCN)CO)CC(=O)N)[C@H](C)CC
InChI InChI=1S/C40H63N9O8S/c1-6-23(3)34-38(55)46-31(20-32(42)51)36(53)45-29(40(57)49(5)26(22-50)11-10-16-41)14-17-58-18-15-33(52)44-30(19-25-21-43-28-13-9-8-12-27(25)28)37(54)47-35(24(4)7-2)39(56)48-34/h8-9,12-13,21,23-24,26,29-31,34-35,43,50H,6-7,10-11,14-20,22,41H2,1-5H3,(H2,42,51)(H,44,52)(H,45,53)(H,46,55)(H,47,54)(H,48,56)/t23-,24+,26+,29+,30-,31+,34+,35+/m1/s1 Key:UGNGRKKDUVKQDF-IHOMMZCZSA-N

See also

• Atosiban
• Epelsiban
• L-368,899
• L-371,257
• Retosiban

References

1. Rainer Landgraf; Inga D. Neumann (10 September 2008). Advances in Vasopressin and Oxytocin - From Genes to Behaviour to Disease. Elsevier. pp. 194, 489. ISBN 978-0-08-093247-7.
2. Stefan Offermanns; Walter Rosenthal (14 August 2008). Encyclopedia of Molecular Pharmacology. Springer Science & Business Media. pp. 1278–. ISBN 978-3-540-38916-3.
3. Richard Ouellette; Joseph Joyce (25 October 2010). Pharmacology for Nurse Anesthesiology. Jones & Bartlett Publishers. pp. 450–. ISBN 978-0-7637-8607-6.